Reimagining Medicine
Company overview
Innovation: Pipeline overview
Financial review
2023 priorities
Appendix
Innovation: Clinical trials
Abbreviations
Novartis pipeline in registration
Solid Tumors
Code
Name
VDT482 tislelizumab
Mechanism
PD1 inhibitor
DRB436 Tafinlar+ MekinistⓇ
BRAF inhibitor + MEK
inhibitor
Indication(s)
2L ESCC
Non-small cell lung cancer
HGG/LGG, pediatrics
Immunology
Code
Name
Mechanism
AIN457
CosentyxⓇ
IL17A inhibitor
IGE025
XolairⓇ
IgE inhibitor
1. Approved in US.
56 Investor Relations | Q4 2022 Results
Indication(s)
Hidradenitis suppurativa
Psoriatic arthritis (IV formulation)
Axial SpA (IV formulation)
Auto-injector
Cardiovascular
Code
LCZ696
Name
Entresto®
1 lead indication
Lead indication
Mechanism
Indication(s)
Angiotensin receptor/neprilysin Congestive heart failure, pediatrics1
inhibitor
NOVARTIS | Reimagining MedicineView entire presentation